19th March 2018
Belfast, U.K. – March 19, 2018.
CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of Richard Milliken, CA as Chairman of the Board of Directors.
“We are pleased to welcome Richard as our Board Chairman, his extensive experience will be instrumental in guiding the company as we develop and expand our pipeline of therapeutic assets across multiple serious disease areas,” stated Robert Ladner, Ph.D., Chief Executive Officer of CV6 Therapeutics.
Richard ‘Dick’ Milliken is the Chairman of Catalyst Inc., (formerly the Northern Ireland Science Park), and the Lotus Group Ltd. He is a Non-Executive Director of Ryanair Plc and the Bank of Ireland Mortgage Bank. Previously, Dick was the CFO and Director of the Almac Group Ltd (a pharmaceutical development and manufacturing organisation), CEO of Lamont Holdings Plc and responsible for the Investment Bank of Ireland Group (wholly owned subsidiary of the Bank of Ireland) activities in Northern Ireland. A graduate of Queen’s University Belfast, Dick qualified as a Chartered Accountant after training with PwC.
“CV6 Therapeutics have developed a tremendously exciting pipeline of new treatments that hold real promise to make a difference in the lives of patients with cancer and other diseases. I’m looking forward to working with the experienced and talented team at CV6 as we push forward with the development of these new therapies.”
CV6 Therapeutics
CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases.
